Pfizer Vaccine Research, Pearl River, NY 10965, USA.
Expert Rev Vaccines. 2011 May;10(5):617-34. doi: 10.1586/erv.11.50.
Challenges remain in developing effective meningococcal vaccines and vaccination programs in both the industrialized and developing worlds. Vaccination programs should ideally provide broad coverage of disease-causing strains to prevent disease and also promote the herd immunity important for extending protection to the at-risk unvaccinated population. The success of meningococcal serogroup C conjugate vaccination programs during the last 10 years demonstrates the tremendous positive impact on human health that may be attainable; however, significant challenges remain to implement effective use of serogroup A vaccines for the developing world and to develop broadly protective vaccines against serogroup B disease. The effectiveness of vaccination programs, and shifts in disease epidemiology, must be monitored continuously to evaluate protection levels and to identify gaps in disease coverage. As these challenges are met, the possibility for removing the fear of meningococcal disease from all societies is now becoming a reality.
在工业化国家和发展中国家，开发有效的脑膜炎球菌疫苗和接种规划仍然面临挑战。接种规划理想情况下应广泛覆盖引起疾病的菌株，以预防疾病，并促进对高危未接种人群的群体免疫至关重要。过去 10 年中脑膜炎球菌 C 群结合疫苗接种规划的成功证明了可能实现的巨大积极影响；然而，在发展中国家有效使用 A 群疫苗和开发针对 B 群疾病的广泛保护疫苗仍然存在重大挑战。必须持续监测疫苗接种规划的效果和疾病流行病学的变化，以评估保护水平，并发现疾病覆盖方面的差距。随着这些挑战的解决，消除所有社会对脑膜炎球菌病的恐惧的可能性正在成为现实。
